Basiliximab
drugOn this page
Also known as CHI-621SDZ-CHI-621SDZCHI621Simulect
Summary
Basiliximab (CHEMBL1201439) is an approved antibody (ATC L04AC02) targeting IL2RA; indicated across 24 conditions including immune system disorder and graft versus host disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AC02
- Targets: 1 (IL2RA)
- Indications: 24 conditions
- Clinical trials: 84
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201439 |
| Name | Basiliximab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AC02 |
Also known as: Basiliximab, CHI-621, SDZ-CHI-621, SDZCHI621, Simulect, BASILIXIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| IL2RA | Interleukin-2 receptor subunit α | Binding | 0.3% | P01589 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): IL2RA.
Top Reactome pathways
4 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| RAF/MAP kinase cascade | 1 | IL2RA |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | 1 | IL2RA |
| Interleukin-2 signaling | 1 | IL2RA |
| Interleukin receptor SHC signaling | 1 | IL2RA |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| inflammatory response to antigenic stimulus | 1 |
| regulation of T cell tolerance induction | 1 |
| apoptotic process | 1 |
| activation-induced cell death of T cells | 1 |
| inflammatory response | 1 |
| immune response | 1 |
| cell surface receptor signaling pathway | 1 |
| Notch signaling pathway | 1 |
| interleukin-2-mediated signaling pathway | 1 |
| positive regulation of activated T cell proliferation | 1 |
| negative regulation of T cell proliferation | 1 |
| positive regulation of T cell differentiation | 1 |
| regulation of T cell homeostatic proliferation | 1 |
| negative regulation of inflammatory response | 1 |
| activated T cell proliferation | 1 |
Indications & clinical
Indications
24 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| immune system disorder | 4 | MONDO:0005046 | EFO:0000540 |
| graft versus host disease | 3 | MONDO:0013730 | EFO:0004599 |
| ischemia reperfusion injury | 3 | MONDO:0005203 | EFO:0002687 |
| pulmonary emphysema | 3 | MONDO:0004849 | EFO:0000464 |
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
| ulcerative colitis | 2 | MONDO:0005101 | EFO:0000729 |
| chronic kidney disease | 2 | MONDO:0005300 | EFO:0003884 |
| uveitis | 2 | MONDO:0020283 | EFO:1001231 |
| Hodgkins lymphoma | 2 | MONDO:0004952 | EFO:0000183 |
| glioblastoma | 2 | MONDO:0018177 | EFO:0000519 |
| focal segmental glomerulosclerosis | 2 | MONDO:0100313 | EFO:0004236 |
| kidney disorder | 2 | MONDO:0005240 | EFO:0003086 |
| nasal cavity and paranasal sinus lethal midline granuloma | 2 | MONDO:0006828 | MONDO:0019472 |
| amyotrophic lateral sclerosis | 2 | MONDO:0004976 | MONDO:0004976 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| acute myeloid leukemia | 1 | MONDO:0018874 | EFO:0000222 |
| plasma cell myeloma | 1 | MONDO:0009693 | EFO:0001378 |
| acute kidney tubular necrosis | 1 | MONDO:0006637 | EFO:1000794 |
| uremia | 1 | MONDO:0007008 | EFO:1001226 |
| DiGeorge syndrome | 1 | MONDO:0008564 | MONDO:0018923 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 84.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 26 |
| PHASE4 | 23 |
| PHASE3 | 16 |
| Not specified | 8 |
| PHASE1 | 5 |
| PHASE2/PHASE3 | 3 |
| PHASE1/PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00113269 | PHASE4 | COMPLETED | Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients |
| NCT00149994 | PHASE4 | COMPLETED | Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients |
| NCT00284947 | PHASE4 | COMPLETED | Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids |
| NCT00296244 | PHASE4 | COMPLETED | Steroid Free Immunosuppression in Liver Transplantation |
| NCT00343226 | PHASE4 | COMPLETED | An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in de Novo Liver Transplantation. |
| NCT00369161 | PHASE4 | COMPLETED | A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients |
| NCT00634920 | PHASE4 | COMPLETED | Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients |
| NCT00717470 | PHASE4 | COMPLETED | A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection |
| NCT00724022 | PHASE4 | COMPLETED | Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation |
| NCT00956293 | PHASE4 | TERMINATED | Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program |
| NCT00965094 | PHASE4 | COMPLETED | Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients |
| NCT01304836 | PHASE4 | COMPLETED | A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids |
| NCT02056938 | PHASE4 | TERMINATED | ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF |
| NCT02123108 | PHASE4 | COMPLETED | Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation |
| NCT02377193 | PHASE4 | COMPLETED | Simulect Versus ATG in Sensitized Renal Transplant Patient |
| NCT02523768 | PHASE4 | TERMINATED | Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment |
| NCT02683291 | PHASE4 | COMPLETED | Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients |
| NCT03006419 | PHASE4 | COMPLETED | Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients |
| NCT03171831 | PHASE4 | UNKNOWN | Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major |
| NCT03794492 | PHASE4 | COMPLETED | Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome |
| NCT04104438 | PHASE4 | COMPLETED | Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant |
| NCT04404127 | PHASE4 | UNKNOWN | Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients |
| NCT06066840 | PHASE4 | UNKNOWN | Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement |
| NCT05385432 | PHASE3 | NOT_YET_RECRUITING | Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies |
| NCT00149890 | PHASE3 | COMPLETED | Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids |
| NCT00154284 | PHASE3 | COMPLETED | Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients |
| NCT00188825 | PHASE3 | COMPLETED | Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant |
| NCT00228020 | PHASE3 | COMPLETED | Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients |
| NCT00238901 | PHASE3 | COMPLETED | Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation |
| NCT00251004 | PHASE3 | COMPLETED | Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients |
| NCT00302497 | PHASE3 | UNKNOWN | EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function |
| NCT00378014 | PHASE3 | COMPLETED | Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy |
| NCT00434811 | PHASE3 | COMPLETED | Islet Transplantation in Type 1 Diabetes |
| NCT00658320 | PHASE3 | COMPLETED | Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids |
| NCT00729768 | PHASE2/PHASE3 | WITHDRAWN | A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation |
| NCT00928811 | PHASE2/PHASE3 | TERMINATED | Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant |
| NCT00933231 | PHASE3 | COMPLETED | Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts |
| NCT01011205 | PHASE3 | COMPLETED | Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation |
| NCT01120028 | PHASE2/PHASE3 | COMPLETED | Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy |
| NCT01239563 | PHASE3 | UNKNOWN | Thymoglobulin Induction in Kidney Transplant Recipients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).